Arrhythmic effects of intermittent dobutamine therapy in chronic heart disease failure

American Journal of Therapeutics

Volumn 5, Issue 6, 1998, Pages 405-411

  Tarján, Jeno ^a   Nagy, Lajos ^a   Liziczai, Imre ^b   Junger, Éva ^c  

^a Markusovszky Teaching Hospital   (Hungary)

^b Department of Pulmonology   (Hungary)

^c Reg Hosp of Komarom Esztergom Co   (Hungary)

Author keywords

Arrhythmia; Chronic heart failure; Dobutamine

Indexed keywords

DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HOLTER MONITORING; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; INTENSIVE CARE; MALE; PRIORITY JOURNAL;

EID: 0031735665     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199811000-00009     Document Type: Article

References (35)

1. Fleg JL, Gottlieb SH, Lakatta EG: Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. Am J Med 1982;73:244-250.
2. Wigle ED: Recent Trends in the Treatment of Congestive Heart Failure. A Report of the Symposium on Hypertension and Heart Failure at the International Congress on Directions in Cardiovascular Advances. Excerpta Medica, 1990, pp 5-6.
3. Belardinelli R, et al: Effetti del training aerobico in pazienti con scompenso cardiaco cronico di grado moderato. G Ital Cardiol 1992;22:919-930.
4. Epstein SE, Braunwald E: The effect of beta-adrenergic blockade on patterns of urinary sodium excretion. Ann Intern Med 1966;65:20-27.
5. 1 receptor down-regulation in heart failure. Circ Res 1986;59:297-308.
6. Cleland JGF, et al: Beta-blocking agents in heart failure. Eur Heart J 1996;17:1629-1639.
7. Slatton ML, Eichhorn EJ: β-Blocker therapy for heart failure. Curr Opin Cardiol 1996;11:263-268.
8. Waagstein F, et al: Apex cardiogram and systolic time intervals in acute myocardial infarction and effect of practolol. Br Heart J 1974;36:1109-1121.
9. Waagstein F, et al: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1994;342: 1441-1446.
10. White M, et al: Role of beta-adrenergic receptor down-regulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1995;76:1271-1276.
11. Kraft-Hunter F, Hinds JE: Cardiac dynamic effects of dobutamine increasing myocardial contractility without changing heart rate, mean aortic pressures and end diastolic volume in conscious instrumented dogs. Fed Proc [Abstract] 1973;32:343.
12. Leier CV, Webel J, Bush C: The cardiovascular effects of the continuous infusion of dobutamine in patients with severe heart failure. Circulation 1977;56:468-472.
13. Leier CV, et al: Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1977;58:466-475.
14. Leier CV, Urwerferth DV: Dobutamine. Ann Intern Med 1983;99:490-496.
15. Ponnambalam S, et al: Myocardial energetics and efficiency in patients with idiopathic cardiomyopathy: response to dobutamine and amrinone. Am Heart J 1990; 119:891-898.
16. Tuttle RR, Mills J: Derives de la dopamine. Belgium patent No. 1973, 789, 51-52.
17. Tuttle RR, Mills J: Dobutamine development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975;36:185-196.
18. Vatner SF, McRitchie RJ, Braunwald E: Effects of dobutamine on left ventricular performance, coronary dynamics and distribution of cardiac output in conscious dogs. J Clin Invest 1974;53:1265-1273.
19. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The 1988 report. Arch Intern Med 1988;148:1023-1038.
20. Akhtar N, et al: Hemodynamic effects of dobutamine in patients with severe heart failure. Am J Cardiol 1975;36: 202.
21. Bergovich J, et al: Hemodynamic effects of a new inotropic agent (dobutamine) in chronic cardiac failure. Br Heart J 1975;37:629-634.
22. Jewitt D, et al: Clinical cardiovascular pharmacology of dobutamine. Lancet 1974;2:263-267.
23. Gillespie TA, et al: Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol 1977;39: 588-594.
24. Liang CS, et al: Conditioning effects of chronic infusions of dobutamine: comparison with exercise training. J Clin Invest 1979;64:613-619.
25. Liang CS, et al: Sustained improvement of cardiac function in patients with congestive heart failure after short term infusion of dobutamine. Circulation 1984;69:113-119.
26. Applefeld MM, et al: Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure. Am J Cardiol 1983;51:455-458.
27. Chatterjee K, Bendersky R, Parmley WW: Dobutamine in heart failure. Eur Heart J 1982;3(suppl D):107.
28. Hodgson JMB, Aja M, Sorkin RP: Intermittent ambulatory dobutamine infusions for patients awaiting cardiac transplantation. Am J Cardiol 1984;53:375-376.
29. Leier CV, et al: Drug-induced conditioning in congestive heart failure. Circulation 1982;65:1382-1387.
30. Unverferth DV, et al: Long-term benefit of dobutamine in patients with congestive cardiomyopathy. Am Heart J 1980;100:622-630.
31. Tarján J: Az intermittáló dobutamin infusio congestiv cardiomyopathiában. Presented at the XXIXth Meeting of Medical Practitioners in Somogy, Siófok, 1987.
32. Tarján J: Dobutrex (dobutamine) infusio tartós hatása congestiv cardiomyopathiában. Presented at the Scientific Meeting of the Society of Hungarian Cardiologists, Balatonfüred, 1988.
33. Tarján J: A chronicus balkamra elegtelenség intermittáló Dobutrex kezelése. Presented at the Joint Session of the Societies of Anaesthesiology and Cardiology, Budapest, 1991.
34. Tarján J: Intermittáló dobutamin a chronicus szívgyengeség kezelésében. Presented at the Scientific Session of the Working Group on Cardiology, Tihany, 1994.
35. Dies F: Intermittent dobutamine in ambulatory patients with chronic cardiac failure. Br J Clin Practice 1986; 45(suppl):37-40.